Mercedes L. S.
- Country
- Spain
- Department
- Hepatology
Research Overview
- Evaluation of the Efficacy and Safety of Obeticholic Acid and Bezafibrate in Patients with Primary Biliary Cholangitis Unresponsive or Intolerant to Ursodeoxycholic Acid
- Phase 3 Multinational Study of Resmetirom in Non-Alcoholic Steatohepatitis Patients to Assess NASH Resolution and Fibrosis Progression Prevention
Data & Insights
Has run more than one trial at 6 of 72 partner sites.
Specializations
Liver Disease Management
This investigator specializes in treating chronic liver conditions, with particular emphasis on non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC).
- NASH Resolution Strategies
- Liver Fibrosis Treatment
- Hepatic Function Assessment
The research focus includes evaluation of novel therapeutic approaches for liver disease management.
Metabolic Therapeutics
Expertise in investigating metabolic treatments, including lanifibranor, semaglutide, and other innovative compounds for liver disorders.
- Metabolic Drug Development
- Clinical Response Assessment
- Long-term Treatment Outcomes
The investigator evaluates therapeutic interventions targeting metabolic pathways in liver disease.
Hepatic Biomarkers
Focused on monitoring liver disease progression through various biomarkers, including alkaline phosphatase (ALP) and NAFLD activity score (NAS).
- Liver Histology Analysis
- Disease Progression Markers
- Treatment Response Indicators
Specializes in assessing therapeutic efficacy through biochemical and histological markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.